Neoplasm Metastasis

• 

  Subject Areas on Research

  • "Thin" malignant melanoma: risk factors and clinical management. 
  • 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management. 
  • 5-Fluorouracil in childhood solid tumors. 
  • 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. 
  • 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. 
  • A Bedside Risk Calculator to Preoperatively Distinguish Follicular Thyroid Carcinoma from Follicular Variant of Papillary Thyroid Carcinoma. 
  • A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. 
  • A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. 
  • A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). 
  • A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. 
  • A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. 
  • A SAGE (serial analysis of gene expression) view of breast tumor progression. 
  • A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. 
  • A branching process model of ovarian cancer. 
  • A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma. 
  • A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The Piedmont Oncology Association experience. 
  • A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. 
  • A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. 
  • A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A pathological fracture and a solitary mass in the right clavicle: an unusual first presentation of HCC and the role of immunohistochemistry. 
  • A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. 
  • A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. 
  • A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. 
  • A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. 
  • A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. 
  • A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. 
  • A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. 
  • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. 
  • A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. 
  • A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. 
  • A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. 
  • A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. 
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. 
  • A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. 
  • A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 
  • A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A rationale for the targeted treatment of oligometastases with radiotherapy. 
  • A review of relative dose intensity and survival in patients with metastatic solid tumors. 
  • A review of stereotactic radiosurgery in the management of brain metastases. 
  • A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. 
  • A systems biology view of cancer. 
  • A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer. 
  • A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. 
  • ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. 
  • ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. 
  • ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. 
  • Abiraterone in metastatic prostate cancer without previous chemotherapy. 
  • Abl kinases are required for invadopodia formation and chemokine-induced invasion. 
  • Ablative Approaches for Pulmonary Metastases. 
  • Abnormal monocyte chemotaxis in patients with breast cancer: evidence for a tumor-mediated effect. 
  • Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. 
  • Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. 
  • Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. 
  • Activation of Rap1 promotes prostate cancer metastasis. 
  • Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. 
  • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. 
  • Acute decompensation after removing a central line: practical approaches to increasing safety in the intensive care unit. 
  • Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. 
  • Adenocarcinoma of the stomach. Changing patterns over the last 4 decades. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. 
  • Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. 
  • Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. 
  • Adrenal Imaging Features Predict Malignancy Better than Tumor Size. 
  • Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. 
  • Alteration in osteoblast activity and nutritional vitamin-D deficiency in non-hypercalcemic malignancy. 
  • Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene. 
  • Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. 
  • Amplification of telomeric DNA directly correlates with metastatic potential of human and murine cancers of various histological origin. 
  • An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. 
  • An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. 
  • An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. 
  • Analysis of results of radiation therapy for Stage II carcinoma of the cervix. 
  • Anchorage-independent cell growth signature identifies tumors with metastatic potential. 
  • Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). 
  • Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics 
  • Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma. 
  • Angiogenesis in non-small cell lung cancer. 
  • Angiotropism of human prostate cancer cells: implications for extravascular migratory metastasis. 
  • Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. 
  • Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. 
  • Anti-EBV serologic tests for nasopharyngeal carcinoma. 
  • Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. 
  • Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. 
  • Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. 
  • Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. 
  • Antimetastatic potential of PAI-1-specific RNA aptamers. 
  • Application of posterior neck dissection in treating malignant melanoma of the posterior scalp. 
  • Are time or intensity factors important to the definition of metastases of unknown origin? 
  • Assessment of advanced gastric cancer management in the United States. 
  • Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. 
  • Association between ratio of matrix metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. 
  • Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. 
  • Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. 
  • Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. 
  • Association of neurologic deficits with surgical outcomes and health-related quality of life after treatment for metastatic epidural spinal cord compression. 
  • Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. 
  • Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. 
  • BCL2 interaction with actin in vitro may inhibit cell motility by enhancing actin polymerization. 
  • BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis. 
  • Bcl-2 accelerates multistep prostate carcinogenesis in vivo. 
  • Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. 
  • Bevacizumab for patients with metastatic renal cancer: an update. 
  • Bevacizumab in colorectal cancer. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 
  • Bilateral adrenal neuroblastoma. 
  • Bilateral pulmonary nodules in a 37-year-old woman with malignant melanoma. Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma). 
  • Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. 
  • Biochemical recurrence of prostate cancer. 
  • Biologic functions of the G12 subfamily of heterotrimeric g proteins: growth, migration, and metastasis. 
  • Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. 
  • Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. 
  • Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. 
  • Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Bone morphogenetic proteins and cancer: review of the literature. 
  • Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. 
  • Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. 
  • Brainstem melanomas presenting as a cavernous malformation. 
  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Breast cancer aggressiveness and racial disparity. 
  • Breast cancer and aging: results of the U13 conference breast cancer panel. 
  • Breast cancer in older women. 
  • Breast cancer in the elderly. Current patterns of care. 
  • Breast cancer, version 3.2013: featured updates to the NCCN guidelines. 
  • Bridging the translational gap: Implementation of multimodal small animal imaging strategies for tumor burden assessment in a co-clinical trial. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. 
  • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. 
  • Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Carcinoid metastatic to the ovary. A clinocopathologic analysis of 35 cases. 
  • Carcinoma of the male urethra. 
  • Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. 
  • Carcinoma of unknown primary: natural history and response to therapy. 
  • Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. 
  • Care of cancer survivors. 
  • Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells. 
  • Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. 
  • Cell invasion through basement membranes: an anchor of understanding. 
  • Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. 
  • Cell-based vaccines for the stimulation of immunity to metastatic cancers. 
  • Central Nervous System Cancers, Version 1.2015. 
  • Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. 
  • Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. 
  • Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. 
  • Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. 
  • Chemosis, proptosis and amaurosis in a 19-year-old male. 
  • Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. 
  • Chemotherapy of brain tumors. 
  • Chest case of the day. Metastatic bronchial carcinoid. 
  • Childhood rhabdomyosarcoma. Analysis of coordinated therapy and results. 
  • Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma. 
  • Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. 
  • Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. 
  • Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. 
  • Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. 
  • Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. 
  • Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential. 
  • Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. 
  • Clear cell hidradenoma: a mimic of metastatic clear cell tumors. 
  • Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy. 
  • Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. 
  • Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. 
  • Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. 
  • Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. 
  • Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). 
  • Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. 
  • Clinical endpoints for drug development in prostate cancer. 
  • Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. 
  • Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. 
  • Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. 
  • Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. 
  • Clinical prognostic model for older patients with advanced non-small cell lung cancer. 
  • Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. 
  • Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate. 
  • Co-morbidities Associated With Early Mortality in Adults With Spina Bifida. 
  • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Colon cancer. 
  • Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-LeX antigens. 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma. 
  • Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. 
  • Commentary: rectal cancer an evolution of treatment. 
  • Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results. 
  • Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. 
  • Comparative effectiveness: 18F-FDG-PET/CT versus CT for post-treatment follow-up of patients with lung cancer. 
  • Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma. 
  • Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. 
  • Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. 
  • Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. 
  • Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T. 
  • Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. 
  • Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. 
  • Computational models of cancer cell transport through the microcirculation. 
  • Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation. 
  • Concomitant renal cell carcinoma and metastatic epithelioid angiosarcoma with microangiopathy. 
  • Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. 
  • Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. 
  • Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. 
  • Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. 
  • Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies. 
  • Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. 
  • Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. 
  • Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. 
  • Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. 
  • Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. 
  • Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. 
  • Current approaches and future strategies for pancreatic carcinoma. 
  • Current management of melanoma. 
  • Current multidisciplinary management of brain metastases. 
  • Current status of endocrine therapy for metastatic breast cancer. 
  • Cutaneous manifestations of internal malignancies: an overview. 
  • Cutaneous metastatic cholangiocarcinoma: a report of three cases and review of the literature. 
  • Cytokinetic and molecular pharmacology studies of arabinosylcytosine in metastatic melanoma. 
  • Cytomorphologic features of sebaceous carcinoma on fine needle aspiration. 
  • Cytopathology of mesenchymal chondrosarcomas: a report and comparison of four patients. 
  • Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. 
  • Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). 
  • Debulking nephrectomy in metastatic renal cancer. 
  • Decreased E-cadherin expression correlates with higher stage of Wilms' tumors. 
  • Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. 
  • Deferred systemic therapy in patients with metastatic renal cell carcinoma. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. 
  • Delivery rate affects uptake of a fluorescent glucose analog in murine metastatic breast cancer. 
  • Delivery-corrected imaging of fluorescently-labeled glucose reveals distinct metabolic phenotypes in murine breast cancer. 
  • Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. 
  • Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. 
  • Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). 
  • Detection of circulating tumor DNA in early- and late-stage human malignancies. 
  • Detection of metastatic tumors in nude mice: brief communication. 
  • Detection of oncornavirus antigenic activity in human urothelial tissues. 
  • Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. 
  • Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. 
  • Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. 
  • Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta-galactosidase. 
  • Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. 
  • Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. 
  • Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. 
  • Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. 
  • Differential production of high molecular weight sulfated glycoproteins in normal colonic mucosa, primary colon carcinoma, and metastases. 
  • Diffuse central neurocytoma with craniospinal dissemination. 
  • Direct correlation between DNA repair capacity and metastatic potential of K-1735 murine melanoma cells. 
  • Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. 
  • Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. 
  • Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. 
  • Disruption of lysosome function promotes tumor growth and metastasis in Drosophila. 
  • Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways. 
  • Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. 
  • Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma. 
  • Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? 
  • Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. 
  • Double antibody radioimmunoassay for monitoring metastatic breast cancer. 
  • Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. 
  • Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. 
  • Dual-energy CT for characterization of adrenal nodules: initial experience. 
  • Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. 
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. 
  • Dynamic prediction of metastases after radical prostatectomy for prostate cancer. 
  • Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. 
  • E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. 
  • EMT and MET: necessary or permissive for metastasis? 
  • ENTPD1 (CD39) Expression Inhibits UVR-Induced DNA Damage Repair through Purinergic Signaling and Is Associated with Metastasis in Human Cutaneous Squamous Cell Carcinoma. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • EUS-guided FNA of pancreatic metastases: a multicenter experience. 
  • Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. 
  • Ectopic expression of mucins in colorectal cancer metastasis. 
  • Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy. 
  • Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. 
  • Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. 
  • Effect of Mts1 on the structure and activity of nonmuscle myosin II. 
  • Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. 
  • Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse. 
  • Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. 
  • Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid. 
  • Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. 
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 
  • Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. 
  • Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. 
  • Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. 
  • Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. 
  • Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 
  • Electronic patient-reported data capture as a foundation of rapid learning cancer care. 
  • Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. 
  • Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. 
  • Endobronchial Carcinoid Tumor Totally Occluding the Left Main Bronchus Without Producing Symptoms of Bronchial Obstruction. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endothelial TRPV4 channels prevent tumor growth and metastasis via modulation of tumor angiogenesis and vascular integrity. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Enhancer-derived long non-coding RNAs CCAT1 and CCAT2 at rs6983267 has limited predictability for early stage colorectal carcinoma metastasis. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. 
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. 
  • Epirubicin and ifosfamide in metastatic breast cancer. 
  • Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion. 
  • Epithelioid and epithelial neoplasms of bone. 
  • Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. 
  • Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. 
  • Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. 
  • Evaluation of the liver for metastatic disease. 
  • Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. 
  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
  • Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. 
  • Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. 
  • Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). 
  • Experimental animal models of pancreatic carcinogenesis and metastasis. 
  • Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. 
  • Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. 
  • Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. 
  • Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. 
  • Extrapulmonary Findings and Malignancies in Participants Screened With Chest CT in the National Lung Screening Trial. 
  • F-18 FDG PET/CT imaging of submandibular gland oncocytoma. 
  • FDG-PET for management of cervical and ovarian cancer. 
  • FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. 
  • Factors associated with survival in pediatric adrenocortical carcinoma: An analysis of the National Cancer Data Base (NCDB). 
  • Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. 
  • Fatty acid metabolites in rapidly proliferating breast cancer. 
  • Feasibility of a mindful yoga program for women with metastatic breast cancer: results of a randomized pilot study. 
  • Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment. 
  • First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. 
  • Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? 
  • Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. 
  • Function of nuclear factor kappaB in pancreatic cancer metastasis. 
  • Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. 
  • G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis. 
  • GPR54 is a target for suppression of metastasis in endometrial cancer. 
  • Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. 
  • Gemcitabine in the management of metastatic breast cancer: a systematic review. 
  • Gender disparities in clinical presentation, treatment, and outcomes in metastatic spine disease. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. 
  • Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. 
  • Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. 
  • Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. 
  • Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. 
  • Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. 
  • Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell cancer patients receiving platinum-based chemotherapy. 
  • Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. 
  • Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 
  • Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. 
  • Genomic and molecular profiling predicts response to temozolomide in melanoma. 
  • Glassy cell carcinoma of the cervix. 
  • Glutathione S-transferase polymorphisms and survival in primary malignant glioma. 
  • Glycoconjugates and tumor metastasis. 
  • Gold nanoparticles-mediated photothermal therapy and immunotherapy. 
  • Gray scale ultrasound and isotope scanning: complementary techniques for imaging the liver. 
  • Hand metastasis from melanoma: a case study. 
  • Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Hemidesmosome-like intercellular specializations in human meningiomas. 
  • Heterogeneity of antigen expression in advanced epithelial ovarian cancer. 
  • Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. 
  • High Dimensional Variable Selection with Error Control. 
  • High-Dose Interleukin-2: Evaluation of a Standardized Order Set for Biotherapy in an Intensive Care Unit
. 
  • High-LET Radiation Increases Tumor Progression in a K-Ras-Driven Model of Lung Adenocarcinoma. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. 
  • High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. 
  • Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. 
  • Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • How Good Is Positron Emission Tomography at Detecting Previously-Occult Metastatic Lung Cancer at Diagnosis? 
  • Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. 
  • Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. 
  • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. 
  • Hyperlucent lung after radiation therapy. 
  • Hypertonic saline-augmented radiofrequency ablation of the VX-2 tumor implanted in the rabbit kidney: a short-term survival pilot study. 
  • I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. 
  • IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 
  • IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). 
  • IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. 
  • Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. 
  • Imaging and Isolation of Extravasation-Participating Endothelial and Melanoma Cells During Angiopellosis. 
  • Immunoglobulin localization in benign and malignant lesions of the human mammary gland. 
  • Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. 
  • Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. 
  • Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. 
  • Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors. 
  • Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. 
  • Immunotherapy for Resected Pulmonary Metastases. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). 
  • Impact of Multidisciplinary Intraoperative Teams on Thirty-Day Complications After Sacral Tumor Resection. 
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. 
  • Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. 
  • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. 
  • Impact of preepiglottic space tumor involvement on concurrent chemoradiation therapy. 
  • Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • Impact of simultaneous diaphragm resection during hepatectomy for treatment of metastatic colorectal cancer. 
  • Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. 
  • Importance of race on breast cancer survival. 
  • Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. 
  • Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. 
  • Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. 
  • In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. 
  • In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. 
  • In vitro chemotherapeutic testing of urologic tumors. 
  • In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. 
  • In vivo label-free photoacoustic flow cytography and on-the-spot laser killing of single circulating melanoma cells. 
  • In vivo selection of tumor-targeting RNA motifs. 
  • Incidence rate of breast cancer in young women. 
  • Incidence rate of breast cancer in young women. 
  • Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. 
  • Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. 
  • Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin-sulfate monoclonal antibody. 
  • Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. 
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. 
  • Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. 
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. 
  • Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. 
  • Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. 
  • Influence of trauma on the unusual distribution of metastases from carcinoma of the larynx. 
  • Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. 
  • Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. 
  • Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. 
  • Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. 
  • Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. 
  • Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. 
  • Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF. 
  • Integrative clinical genomics of advanced prostate cancer. 
  • Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. 
  • Intercellular junctions and tumor behavior in lung cancer. 
  • Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. 
  • International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. 
  • Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment. 
  • Intraocular Teratoid Medulloepithelioma Presenting With a Completely Rhabdomyosarcomatous Distant Metastasis. 
  • Intrauterine diethylstilbestrol exposure and its consequences: pathologic characteristics of vaginal adenosis, clear cell adenocarcinoma, and related lesions. 
  • Intravascular location of breast cancer cells after spontaneous metastasis to the lung. 
  • Intravital fluorescence facilitates measurement of multiple physiologic functions and gene expression in tumors of live animals. 
  • Investigational therapies for brain metastases. 
  • Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. 
  • Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion? 
  • Isolated limb infusion as a model to test new agents to treat metastatic melanoma. 
  • Isolation of a human prostate carcinoma cell line (DU 145). 
  • Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin β3 recycling, cell migration and cancer metastasis. 
  • JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. 
  • Juvenile malignant melanoma. 
  • KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. 
  • LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. 
  • Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. 
  • Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 
  • Lesions of bone and bladder cancer. 
  • Lethal "thin" malignant melanoma. Identifying patients at risk. 
  • Leukaemia: a model metastatic disease. 
  • Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. 
  • Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk. 
  • Liver and prostate adenocarcinoma: an "estrogen-free" environment? 
  • Liver metastases from breast cancer: long-term survival after curative resection. 
  • Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. 
  • Long-term follow-up after uveal melanoma charged particle therapy. 
  • Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. 
  • Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. 
  • Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. 
  • Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. 
  • Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. 
  • Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. 
  • Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. 
  • Lysyl oxidase is essential for hypoxia-induced metastasis. 
  • MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. 
  • MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. 
  • MOLECULAR PROGNOSTICS FOR UVEAL MELANOMA. 
  • MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. 
  • Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. 
  • Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. 
  • Making genuine progress against metastatic breast cancer. 
  • Malignant Melanoma: Diagnostic and Management Update. 
  • Malignant giant cell tumor of synovium (malignant pigmented villonodular synovitis). 
  • Malignant melanoma and pregnancy. 
  • Malignant melanoma arising during pregnancy. A study of 100 patients. 
  • Malignant melanoma in the elderly. 
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Management of metastatic prostatic cancer. 
  • Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). 
  • Management of unresectable non-small cell carcinoma of the lung (NSCLC). 
  • Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. 
  • Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. 
  • Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells. 
  • Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. 
  • Mesenteric tumour deposits arising from small-intestine neuroendocrine tumours are frequently associated with fibrosis and IgG4-expressing plasma cells. 
  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. 
  • Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment. 
  • Metastases in the pancreas from nonhematologic neoplasms: report of 20 cases evaluated by fine-needle aspiration. 
  • Metastasis dynamics for non-small-cell lung cancer: effect of patient and tumor-related factors. 
  • Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. 
  • Metastatic Lung Cancer and Distress: Use of the Distress Thermometer for Patient Assessment. 
  • Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. 
  • Metastatic behavior and cell surface properties of HT-29 human colon carcinoma variant cells selected for their differential expression of sialyl-dimeric Le(x)-antigen. 
  • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. 
  • Metastatic carcinoma of the iris. 
  • Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. 
  • Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. 
  • Metastatic patterns in adenocarcinoma. 
  • Metastatic prostate cancer in a transgenic mouse. 
  • MicroRNA expression characterizes oligometastasis(es). 
  • MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model. 
  • MicroRNA-16 suppresses metastasis in an orthotopic, but not autochthonous, mouse model of soft tissue sarcoma. 
  • MicroRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. 
  • MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. 
  • Migration of human dendritic cells after injection in patients with metastatic malignancies. 
  • Mindful Yoga for women with metastatic breast cancer: design of a randomized controlled trial. 
  • Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. 
  • Modulation of the transformed and neoplastic phenotype of rat fibroblasts by MHC-I gene expression. 
  • Molecular and clonal evolution in recurrent metastatic gliosarcoma. 
  • Molecular biologic staging of esophageal cancer. 
  • Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. 
  • Molecular mechanisms underlying the potentially adverse effects of folate. 
  • Monoclonal antibody against human colonic sulfomucin: immunochemical detection of its binding sites in colonic mucosa, colorectal primary carcinoma, and metastases. 
  • Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. 
  • Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. 
  • Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. 
  • Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. 
  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 
  • Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Musculoskeletal syndromes associated with malignancy. 
  • Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. 
  • Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. 
  • Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. 
  • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 
  • Natural history of renal cell carcinoma. 
  • Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis. 
  • Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. 
  • Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. 
  • New drug development in metastatic prostate cancer. 
  • Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. 
  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. 
  • Nivolumab: Immunotherapy in Malignant Melanoma. 
  • Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-randomized comparative study of irradiation alone or in combination with surgery in stage Ib, IIa and "proximal" IIb carcinoma of the cervix. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer: FDG-PET imaging. 
  • Non-specific and specific immunotherapy in patients with melanoma. 
  • Noninvasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. 
  • Novel therapies are changing treatment paradigms in metastatic prostate cancer. 
  • Nutritional parameters affecting erythrocyte polyamine levels in cancer patients. 
  • OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential. 
  • Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Obstructive and perforative colonic carcinoma: patterns of failure. 
  • Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. 
  • Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. 
  • Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 
  • Oral candidiasis in cancer patients. 
  • Orbital phlebography in the study of cavernous sinus disease. 
  • Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds. 
  • Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. 
  • Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. 
  • Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells. 
  • Osteopontin: regulation in tumor metastasis. 
  • Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. 
  • Ovarian teratoma with glial implants on the peritoneum. An analysis of 12 cases. 
  • Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. 
  • Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. 
  • Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. 
  • Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. 
  • Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. 
  • Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. 
  • Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer. 
  • Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Parenting while living with advanced cancer: A qualitative study. 
  • Partner-delivered reflexology: effects on cancer pain and anxiety. 
  • Pathology of vaginal and cervical abnormalities associated with prenatal exposure to diethylstilbestrol (des). 
  • Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. 
  • Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. 
  • Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. 
  • Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases. 
  • Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. 
  • Pericyte-like location of GFP-tagged melanoma cells: ex vivo and in vivo studies of extravascular migratory metastasis. 
  • Pericytic-like angiotropism of glioma and melanoma cells. 
  • Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents. 
  • Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. 
  • Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. 
  • Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. 
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. 
  • Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. 
  • Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. 
  • Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. 
  • Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. 
  • Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. 
  • Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. 
  • Phase I Study of Muscadine Grape Extract for Patients With Advanced Cancer. 
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. 
  • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. 
  • Phase I study of Doxil and vinorelbine in metastatic breast cancer. 
  • Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. 
  • Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. 
  • Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). 
  • Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. 
  • Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial. 
  • Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. 
  • Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. 
  • Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. 
  • Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. 
  • Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. 
  • Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. 
  • Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. 
  • Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. 
  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. 
  • Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. 
  • Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. 
  • Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. 
  • Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. 
  • Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis. 
  • Physics and imaging for targeting of oligometastases. 
  • Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). 
  • Plasma dopamine-beta-hydroxylase in the diagnosis of neuroblastoma. 
  • Plectin is a regulator of prostate cancer growth and metastasis. 
  • Pleural effusion and renal cell carcinoma: an angiographic-pathologic correlation. 
  • Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. 
  • Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. 
  • Possible role of cell cycle-dependent morphology, geometry, and mechanical properties in tumor cell metastasis. 
  • Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. 
  • Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. 
  • Predicting the sites of metastases from lung cancer using molecular biologic markers. 
  • Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. 
  • Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 
  • Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. 
  • Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. 
  • Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. 
  • Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. 
  • Preoperative irradiation for tethered rectal carcinoma. 
  • Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. 
  • Prevalence and factors associated with diagnosed depression among hospitalized cancer patients with metastatic disease. 
  • Prevalence of human papillomavirus types 16 and 18 in squamous-cell carcinoma of the penis: a retrospective analysis of primary and metastatic lesions by differential polymerase chain reaction. 
  • Profiles of brain metastases: Prioritization of therapeutic targets. 
  • Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. 
  • Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer. 
  • Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. 
  • Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. 
  • Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. 
  • Prognostic factors in the initial response to therapy by patients with advanced breast cancer. 
  • Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. 
  • Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. 
  • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. 
  • Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. 
  • Progression of hepatic neoplasia in medaka (Oryzias latipes) exposed to diethylnitrosamine. 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Promoter hypermethylation profile of kidney cancer. 
  • Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. 
  • Prostate cancer metastasis-suppressor genes: a current perspective. 
  • Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. 
  • Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. 
  • QOL and outcomes research in prostate cancer patients with low socioeconomic status. 
  • Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). 
  • Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen. 
  • RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. 
  • Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. 
  • Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. 
  • Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation. 
  • Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. 
  • Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer. 
  • Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. 
  • Radiation therapy for oligometastatic non-small cell lung cancer. 
  • Radical irradiation of extracranial oligometastases. 
  • Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. 
  • Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. 
  • Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. 
  • Radioisotope bone scanning characteristics of metastatic skeletal deposits of prostatic adenocarcinoma. 
  • Radionuclide emission computed tomography of the head with 99mTc and a scintillation camera. 
  • Radiotherapy alone for carcinoma of the vagina: the importance of overall treatment time. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. 
  • Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. 
  • Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. 
  • Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. 
  • Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. 
  • Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. 
  • Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. 
  • Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 
  • Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. 
  • Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. 
  • Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. 
  • Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. 
  • Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. 
  • Relationship between histopathology and in vitro clonogenicity in breast cancer. 
  • Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. 
  • Renal metastasis of adenocarcinoma of the lung: massive hematuria managed by therapeutic embolization. 
  • Resident memory T cells in tumor-distant tissues fortify against metastasis formation. 
  • Response of the secretory immune system to bronchogenic carcinoma of the lung. 
  • Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. 
  • Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. 
  • Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. 
  • Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. 
  • Rhabdomyosarcoma in adult prostate. 
  • Rheumatologic manifestations of cancer. 
  • Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. 
  • Role of incipient angiogenesis in cancer metastasis. 
  • Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. 
  • Role of transforming growth factor Beta in human cancer. 
  • Role of transforming growth factor beta in human disease. 
  • SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. 
  • STING suppresses bone cancer pain via immune and neuronal modulation. 
  • SV40-transformed hamster prostatic tissue: a model of human prostatic malignancy. 
  • Safety and technique of ferumoxytol administration for MRI. 
  • Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. 
  • Salting the Soil: Targeting the Microenvironment of Brain Metastases. 
  • Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. 
  • Secondary cancers after bone marrow transplantation. 
  • Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. 
  • Selective upregulated expression of the alpha2-macroglobulin signaling receptor in highly metastatic 1-LN prostate carcinoma cells. 
  • Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. 
  • Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. 
  • Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall. 
  • Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. 
  • Should abdominal cluster transplantation be abandoned? 
  • Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. 
  • Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis. 
  • Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. 
  • Simultaneous in vivo optical quantification of key metabolic and vascular endpoints reveals tumor metabolic diversity in murine breast tumor models. 
  • Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. 
  • Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. 
  • Skeletal metastases of melanoma. 
  • Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. 
  • Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. 
  • Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. 
  • Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Staging techniques for lung cancer. 
  • Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. 
  • Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. 
  • Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? 
  • Stereotactic body radiotherapy treatment of extracranial metastases. 
  • Subacute headache in a patient with metastatic gastric cancer. 
  • Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. 
  • Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). 
  • Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. 
  • Sulfonylurea receptor 1 expression is variable in adult and pediatric brain tumors. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. 
  • Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. 
  • Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. 
  • Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone. 
  • Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. 
  • Surgical management of Merkel cell carcinoma. 
  • Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. 
  • Surgical management of melanoma brain metastases in patients treated with immunotherapy. 
  • Surgical options for advanced/metastatic gastrointestinal stromal tumors. 
  • Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. 
  • Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. 
  • Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. 
  • Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries? 
  • Synchronous primary carcinoma of breast and ovary versus ovarian metastases. 
  • Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers. 
  • Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. 
  • Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. 
  • Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. 
  • Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review. 
  • T cells in ovarian cancer. 
  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. 
  • TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology. 
  • TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. 
  • TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. 
  • Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. 
  • Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. 
  • Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. 
  • Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. 
  • Targeting ovarian cancer-initiating cells. 
  • Technology evaluation: Rexin-G, Epeius Biotechnologies. 
  • Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • The Biology of Pulmonary Metastasis. 
  • The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease. 
  • The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. 
  • The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. 
  • The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways. 
  • The Molecular Taxonomy of Primary Prostate Cancer. 
  • The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. 
  • The biology of ovarian cancer. 
  • The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. 
  • The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. 
  • The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. 
  • The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model. 
  • The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. 
  • The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. 
  • The evolving role of radiotherapy in treatment of oligometastatic NSCLC. 
  • The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? 
  • The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. 
  • The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats. 
  • The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. 
  • The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. 
  • The natural course of prostatic carcinoma in relation to initial cytological grade. 
  • The oligometastatic state - separating truth from wishful thinking. 
  • The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. 
  • The prognostic significance of angiogenesis in epithelial ovarian carcinoma. 
  • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. 
  • The role of Osteopontin in tumor metastasis. 
  • The role of WNT10B in normal prostate gland development and prostate cancer. 
  • The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. 
  • The role of radiation therapy in the management of metastatic renal cell carcinoma. 
  • The role of radiation treatment in metastatic prostate cancer. 
  • The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. 
  • The significance of distant metastases in breast cancer. 
  • The spectrum of small bowel melanoma. 
  • The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. 
  • The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. 
  • The type III TGF-beta receptor suppresses breast cancer progression. 
  • The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. 
  • The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. 
  • The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. 
  • Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. 
  • Thoracolumbar vertebral reconstruction after surgery for metastatic spinal tumors: long-term outcomes. 
  • Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. 
  • Thymoma with distant metastases. 
  • Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. 
  • Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. 
  • Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review. 
  • Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. 
  • Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. 
  • Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. 
  • Transforming growth factor-beta differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1. 
  • Transplanted carcinoma in an immunosuppressed patient. 
  • Transthoracic fine needle aspiration biopsy. Sensitivity in relation to guidance technique and lesion size and location. 
  • Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. 
  • Trastuzumab emtansine for HER2-positive advanced breast cancer. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. 
  • Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. 
  • Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. 
  • Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. 
  • Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. 
  • Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. 
  • Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. 
  • Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. 
  • Tumors of the Epiphyses. 
  • Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. 
  • Ulex europeus agglutinin I-reactive high molecular weight glycoproteins of adenocarcinoma of distal colon and rectum and their possible relationship with metastatic potential. 
  • Ultrastructure of primary and metastatic ovarian carcinoids: analysis of 11 cases. 
  • Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. 
  • Unraveling the molecular nature of melanin changes in metastatic cancer 
  • Updates in advanced prostate cancer 2018. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. 
  • Use of bioluminescence imaging to detect enhanced hepatic and systemic tumor growth following partial hepatectomy in mice. 
  • Use of gene expression and pathway signatures to characterize the complexity of human melanoma. 
  • Uterine Neoplasms. Clinical Practice Guidelines in Oncology. 
  • Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. 
  • Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. 
  • Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. 
  • Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity. 
  • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. 
  • Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. 
  • Virus-induced genitourinary malignancy. Macromolecular identity. 
  • Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. 
  • Wnts and the hallmarks of cancer. 
  • X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model. 
  • Yes or no to local therapy for oligometastatic prostate cancer? 
  • Yoga for women with metastatic breast cancer: results from a pilot study. 
  • [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway]. 
  • mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma. 
  • miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. 
  • microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). 
  • nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. 
  • p38 MAPK in development and cancer. 
  • p53 gene mutation spectrum in human unknown primary tumors. 
  • p53 regulates the expression of the tumor suppressor gene maspin. 
  • ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. 
  • β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bradford, William Dalton, Professor of Pathology, Pathology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society